Generalized erythematous scaly rash after glucocorticoids

A 65-years-old woman with a medical history of idiopathic throm- bocytopenic purpura and psoriasis in treatment with topical glucocor- ticoids presented with a three-month history of burning, generalized erythematous, scaly rash, and chills. A few weeks before the rash, the patient presented petechiae on her thighs due to a low platelet count (28.000 platelets per microliter), for which she started treatment with prednisone 25 mg/week. The rash was initially treated with topical ointments including clobetasol, urea, salicylic acid, ammonium lactate, and propylene glycol without improvement. The physical examination showed generalized erythroderma (Fig. 1A) from neck to feet (Fig. 1B), with thick silvery desquamation respecting the face and back of the legs (Fig. 1C), involving more than 90% of the patient’s body surface area and erythematous scaly plaques on the scalp. Laboratory test results were normal. A punch biopsy specimen obtained from an arm area showed increased keratinization at the level of the corneal layer with compact parakeratosis with abundant polymorphonuclear cells. The epidermis presented psoriasiform hyperplasia with significant spongio- sis. What is the diagnosis

Infecciones más comunes en el paciente trasplantado

Organ transplantation has become one of the most important areas of medical research and, at present, is still the only therapeutical tool for several diseases. However, there are a number of factors related to transplantation, like immunosuppression and prolonged neutropenia that affect the incidence of infection. These infections are somehow peculiar to trasplant recipients. In fact, there are infectious diseases that only occur in immunodepression situations and, moreover, clinical expression of these infectious diseases can be quite different from that in immunocompetent patients. Besides these aspects, some infections, due to the high prevalence described, must be considered for prevention strategies because they continue to be a principal cause of morbidity and mortality, either due to direct effects or to their implication in the pathogenesis of rejection. These strategies commence before trasplantation by active immunization through vaccine administration to the patient and to people in the milieu and continue after trasplantation with prophylaxis or pre-emptive therapy. The importance of infectious diseases in the evolution and prognosis of trasplant recipients gives a special meaning to the understanding of associated infections, their clinical expression and ways of prevention and treatment

Pneumatocele formation following COVID-19 pneumonia

A 61-year-old man with no significant medical history presented to the emergency department with worsening dyspnea a week after close con-tact with someonewhohad COVID-19. Hewas unvaccinated. He washypoxemic, and the chest radiograph showed bilateralopacities consistent withCOVID-19 pneumonia and tested positive for RNA from SARS-CoV-2. Blood tests showed raised inflammatory markers. Computed tomography (CT)of the chest demonstrated bilateralground-glass opacities. Thepatient washospitalized andtreated with high-flow nasaloxygentherapy, dexameth-asone, and sarilumab. His clinical status improved, and hewas discharged home after 1 week of hospitalization.Three weekslater, hepresented againwith worsening dyspnea, fever, and pleuritic chest pain. A CT pulmonary angiography ruled out pulmonary embolism (Fig. 1A, B) but demonstrated athin-walled cystic lesion with an air–fluid level (Fig. 1A, arrowheads) that suggested an infected pneumatocele. The patient was managed conserva-tively with amoxicillin/clavulanic acid for 3 weeks. During the follow-up, the patient reported the disappearance of symptomatology

Protocolos de estimulación ovárica en inseminación artificial según el patrón utilizado de glicosilación de la hormona folículo estimulante.

ANTECEDENTES: los estudios clínicos que comparan diferentes protocolos de estimulación ovárica no son concluyentes. Nuestro estudio compara tres protocolos según el patrón de glicosilación de la hormona folículo estimulante (FHS) que imita el ciclo natural para inseminación artificial. OBJETIVO: proponer un protocolo de estimulación ovárica secuencial con FSH urinaria (isoforma ácida) seguido de FSH recombinante (isoforma menos ácida) y evaluar su efectividad respecto de los esquemas tradicionales de estimulación con FSH recombinante (FSHr) y FSH urinaria (FSHu). MATERIALES Y MÉTODOS: estudio de cohortes, retrospectivo, efectuado entre mayo de 2012 y mayo 2015 en parejas infértiles en protocolo de inseminación artificial. El grupo de estudio se dividió en tres: 1) FSHr, 2) FSHhp y 3) estimulación sequencial: FSHhp + FSHr. Para el análisis estadístico se utilizaron χ2, ANOVA o test Mann-Whitney. Los resultados se reportan con límite de significación de p < 0.05. RESULTADOS: se estudiaron 178 parejas infértiles en protocolo de inseminación artificial y se efectuaron 299 ciclos de estimulación ovárica con inseminación artificial; grupo 1) 99 con FSHr, 2)100 con FSHhp y 3) 100 con estimulación sequencial: FSHhp + FSHr. Los resultados gestacionales fueron mayores en el grupo FSHu y secuencial. En el análisis costo-efectividad se observó menor tasa con el esquema secuencial en comparación con los otros dos. Al comparar los tres protocolos según los intentos previos de inseminación, en la serie con intentos previos, se encontraron diferencias estadísticamente significativas en βHCG y gestación al comparar FSHr versus secuencial. El protocolo FSHr fue menos efectivo que los otros dos tratamientos. CONCLUSIONES: se planteó la estimulación ovárica controlada con protocolo secuencial en pacientes que recibirían inseminación artificial y, aunque no se encontraron diferencias significativas, sí se observó una tendencia en la que tanto la dosis como los días de estimulación requerida son menores con este protocolo que con los clásicos con FSHr o FSHu.post-print595 K

Biofilms bacterianos e infección

En los países desarrollados tendemos a pensar que las principales causas de mortalidad son las enfermedades cardiovasculares y el cáncer en sus múltiples modalidades. Sin embargo, los datos en Europa resultan elocuentes; las enfermedades infecciosas representan la segunda causa de mortalidad (14,9 millones de muertes), después de las enfermedades cardiovasculares (16,9 millones de muertes) y causan el doble de muertes que el cáncer (7,1 millones de muertes) (datos del World Health Organization, WHO, 2002). Los agentes infecciosos responsables de mortalidad en el hombre han ido evolucionando a medida que las medidas higiénicas y las técnicas médicas han ido evolucionando. Actualmente, las enfermedades infecciosas agudas causadas por bacterias patógenas especializadas como la difteria, tétanos, peste, cólera o la tosferina, que representaban la principal causa de muerte a principios del siglo XX, han sido controladas gracias a la acción de los antibióticos y de las vacunas. En su lugar, más de la mitad de las infecciones que afectan a pacientes ligeramente inmunocomprometidos son producidas por bacterias ubicuas, capaces de producir infecciones de tipo crónico, que responden pobremente a los tratamientos antibióticos y no pueden prevenirse mediante inmunización. Ejemplos de estas infecciones son la otitis media, endocarditis de válvulas nativas, infecciones urinarias crónicas, infecciones de próstata, osteomielitis y todas las infecciones relacionadas con implantes. El análisis directo de los implantes y tejidos de estas infecciones muestra claramente que en la mayoría de los casos la bacteria responsable de la infección crece adherida sobre el tejido o el implante formando comunidades de bacterias a las que se les ha denominado “biofilms”. Dentro del biofilm, las bacterias están protegidas de la acción de los anticuerpos, del ataque de las células fagocíticas y de los tratamientos antimicrobianos. En este artículo se describe el papel que juegan los biofilms en infecciones humanas persistentes

Sellado antibiótico de catéteres intravasculares centrales. Presentación de un caso tipo y de un protocolo de sellado antibiótico

El uso de catéteres intravasculares tunelizados centrales supone una aportación fundamental a la medicina moderna. La infección asociada a estos dispositivos es una de las causas más frecuentes de infección nosocomial en nuestro medio. La simple retirada de un catéter infectado puede ser suficiente para el control de la infección, sin embargo, en muchos casos esta retirada es problemática. En este trabajo se presenta un protocolo de sellado antibiótico aplicable a pacientes diagnosticados de infección asociada a catéter.Use of central intravascular catheters is a common practice in our hospital. Catheter related infection is a major cause of nosocomial infection. Withdrawal can be enough to manage these infections, but this is not always possible. In this article we present an antibiotic lock therapy protocol that can be used in catheter related infection

Long-term catheterization: current approaches in the diagnosis and treatment of port-related infections

Since the first description in 1982, totally implanted venous access ports have progressively improved patients' quality of life and medical assistance when a medical condition requires the use of long-term venous access. Currently, they are part of the standard medical care for oncohematologic patients. However, apart from mechanical and thrombotic complications, there are also complications associated with biofilm development inside the catheters. These biofilms increase the cost of medical assistance and extend hospitalization. The most frequently involved micro-organisms in these infections are gram-positive cocci. Many efforts have been made to understand biofilm formation within the lumen catheters, and to resolve catheter-related infection once it has been established. Apart from systemic antibiotic treatment, the use of local catheter treatment (ie, antibiotic lock technique) is widely employed. Many different antimicrobial options have been tested, with different outcomes, in clinical and in in vitro assays. The stability of antibiotic concentration in the lock solution once instilled inside the catheter lumen remains unresolved. To prevent infection, it is mandatory to perform hand hygiene before catheter insertion and manipulation, and to disinfect catheter hubs, connectors, and injection ports before accessing the catheter. At present, there are still unresolved questions regarding the best antimicrobial agent for catheter-related bloodstream infection treatment and the duration of concentration stability of the antibiotic solution within the lumen of the port

Non-O1 Vibrio cholerae inguinal skin and soft tissue infection with bullous skin lesions in a patient with a penis squamous cell carcinoma

Vibrio spp. is a pathogen rarely isolated in cancer patients, and in most cases it is associated with haematological diseases. Cutaneous manifestations of this organism are even rarer. We report a case of Non-O1 Vibrio cholerae inguinal skin and soft tissue infection presenting bullous skin lesions in a young type II diabetic patient with a penis squamous cell carcinoma having a seawater exposure history

Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism

Mitochondrial toxicity has been recently suggested to be the underlying mechanism of long-term linezolid-associated toxicity in patients with 16S rRNA genetic polymorphisms. Here, we report for the first time two cases of lactic acidosis due to long-term linezolid exposure in liver transplant recipients who presented an A2706G mitochondrial DNA polymorphism

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients : Protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

Altres ajuts: The BEATLE study is a non-commercial, investigator-driven clinical trial funded by the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005; RD16/0016/0010) The Spanish Clinical Research Network (SCReN) provides clinical trial data monitoring and oversees pharmacovigilance (PT17/0017/0010).Background: Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. Methods: A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion: Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. Trial registration: European Clinical Trials Database: EudraCT 2018-001476-37. ClinicalTrials.gov, ID: NCT04233996